Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Hormone receptor-positive (HR+)/HER2-negative is the most frequent subgroup of metastatic breast cancer (MBC). Important therapeutic advances in the treatment of this tumor type have been observed in the last 20 years, with the approval of numerous endocrine therapies (ET) with or wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schettini, Francesco, Giuliano, Mario, Giudici, Fabiola, Conte, Benedetta, De Placido, Pietro, Venturini, Sergio, Rognoni, Carla, Di Leo, Angelo, Locci, Mariavittoria, Jerusalem, Guy, Del Mastro, Lucia, Puglisi, Fabio, Conte, PierFranco, De Laurentiis, Michelino, Pusztai, Lajos, Rimawi, Mothaffar F., Schiff, Rachel, Arpino, Grazia, De Placido, Sabino, Prat, Aleix, Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004645/
https://www.ncbi.nlm.nih.gov/pubmed/33810205
http://dx.doi.org/10.3390/cancers13061458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004645/
https://www.ncbi.nlm.nih.gov/pubmed/33810205
http://dx.doi.org/10.3390/cancers13061458

Ejemplares similares